SCHEMBL2769418

SCHEMBL2769418

CC(=O)NCCNC(=O)c1cccc2c1CCc1cccc3[nH]nc-2c13

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABL1 P00519 9/20 0.46
BCR P11274 9/20 0.46
MAPK8 P45983 2/20 0.43
MAPK9 P45984 2/20 0.43
MAPK10 P53779 2/20 0.43
NPC1 O15118 3/20 0.40
RAB9A P51151 2/20 0.40
KDR P35968 3/20 0.39
KIT P10721 2/20 0.39
FLT1 P17948 2/20 0.39
KDM4E B2RXH2 3/20 0.38
ALDH1A1 P00352 3/20 0.38
HPGD P15428 2/20 0.38
DRD2 P14416 1/20 0.37
DRD4 P21917 1/20 0.37
DRD3 P35462 1/20 0.37
MAPT P10636 2/20 0.36
TP53 P04637 1/20 0.36
GLA P06280 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2771074 0.87 NPC1 (0.46) ABL1BCRMAPK8MAPK9MAPK10
SCHEMBL2768161 0.82 KDR (0.50) MAPK8MAPK9MAPK10NPC1RAB9A
SCHEMBL2768451 0.80 NPSR1 (0.47) MAPK8KDM4EALDH1A1HPGDMAPT
SCHEMBL2768004 0.80 MAPK8 (0.52) MAPK8MAPK9MAPK10NPC1RAB9A
SCHEMBL2768810 0.79 KMT2A (0.50) MAPK10ALDH1A1HPGDSMN1; SMN2MEN1
SCHEMBL2769382 0.79 NPC1 (0.44) ABL1BCRMAPK8MAPK9MAPK10
SCHEMBL2768700 0.73 MAPK10 (0.52) ABL1MAPK8MAPK9MAPK10NPC1
SCHEMBL2771305 0.72 MAPK8 (0.57) ABL1MAPK8MAPK9MAPK10NPC1
SCHEMBL2768727 0.70 MAPK8 (0.52) MAPK8MAPK9MAPK10NPC1RAB9A
SCHEMBL2771632 0.70 MAPK8 (0.44) MAPK8MAPK9MAPK10NPC1KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1479670-B1 NOVEL FUSED RING INDAZOLE COMPOUNDS EISAI R&D MAN CO LTD (JP) 2010-04-21 EP disclosed
EP-1479670-B1 NOVEL FUSED RING INDAZOLE COMPOUNDS EISAI R&D MAN CO LTD (JP) 2010-04-21 EP disclosed
US-7390797-B2 Fused indazole compounds EISAI CO., LTD. (JP) 2008-06-24 US disclosed
US-7390797-B2 Fused indazole compounds EISAI CO., LTD. (JP) 2008-06-24 US disclosed
US-7390797-B2 Fused indazole compounds EISAI CO., LTD. (JP) 2008-06-24 US disclosed
US-20060111419-A1 Novel fused indazole compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2006-05-25 US disclosed
EP-1479670-A1 NOVEL FUSED RING INDAZOLE COMPOUNDS Eisai Co., Ltd. (JP) 2004-11-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060111419-A1 Novel fused indazole compounds MAP2K3, MAP3K11, MAP2K2 ABL1 189/4885BCR 518/4885MAPK8 38/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.